全文获取类型
收费全文 | 815篇 |
免费 | 28篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 28篇 |
妇产科学 | 3篇 |
基础医学 | 84篇 |
口腔科学 | 2篇 |
临床医学 | 58篇 |
内科学 | 198篇 |
皮肤病学 | 7篇 |
神经病学 | 8篇 |
特种医学 | 77篇 |
外科学 | 62篇 |
综合类 | 52篇 |
预防医学 | 29篇 |
药学 | 58篇 |
中国医学 | 1篇 |
肿瘤学 | 182篇 |
出版年
2021年 | 7篇 |
2019年 | 11篇 |
2017年 | 6篇 |
2016年 | 10篇 |
2014年 | 6篇 |
2013年 | 10篇 |
2012年 | 18篇 |
2011年 | 25篇 |
2010年 | 14篇 |
2009年 | 14篇 |
2008年 | 28篇 |
2007年 | 22篇 |
2006年 | 26篇 |
2005年 | 31篇 |
2004年 | 29篇 |
2003年 | 28篇 |
2002年 | 17篇 |
2001年 | 17篇 |
2000年 | 16篇 |
1999年 | 24篇 |
1998年 | 36篇 |
1997年 | 28篇 |
1996年 | 27篇 |
1995年 | 13篇 |
1994年 | 22篇 |
1993年 | 21篇 |
1992年 | 22篇 |
1991年 | 20篇 |
1990年 | 29篇 |
1989年 | 31篇 |
1988年 | 30篇 |
1987年 | 23篇 |
1986年 | 20篇 |
1985年 | 17篇 |
1984年 | 8篇 |
1983年 | 11篇 |
1982年 | 14篇 |
1981年 | 8篇 |
1980年 | 8篇 |
1979年 | 9篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1975年 | 7篇 |
1974年 | 6篇 |
1973年 | 11篇 |
1969年 | 8篇 |
1968年 | 6篇 |
1967年 | 5篇 |
1966年 | 5篇 |
排序方式: 共有850条查询结果,搜索用时 15 毫秒
1.
2.
3.
Eighty-seven consecutive patients with metastatic breast cancer were treated with aminoglutethimide plus hydrocortisone. All patients were postmenopausal and had progressive disease following prior chemotherapy and endocrine therapy. Eighty-five women were evaluable for drug response. One patient showed complete remission and 14 patients partial response, for an overall response rate of 17%. The median duration of response was 11+ months. The response rate was highest in the presence of soft tissue involvement (36%). The most common side effects were transient skin rash, lethargy, and dizziness. Two patients discontinued treatment because of cutaneous allergy. Aminoglutethimide can be considered a moderately active agent when utilized as second- or third-line hormonal therapy. 相似文献
4.
5.
6.
M Kaplan HJ Vreman C Hammerman C Leiter B Rudensky MG MacDonald DK Stevenson 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):455-457
The incidence (%) of hyperbilirubinemia (serum bilirubin ≥257 μmol/l) was similar in neonates with a combination of ABO incompatibility and glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (45%), with ABO incompatibility (54%) or G-6-PD deficiency (37%), alone (ns). Carboxyhemoglobin values, corrected for inspired CO, were similarly elevated in all three groups (0.87 ± 0.32%, 0.82 ± 0.29%, 0.76 ± 0.18%, respectively, ns), but correlated with bilirubin only in those with ABO incompatibility alone. ABO-incompatible/G-6-PD-deficient neonates, compared with those with either condition alone, are not at increased risk for hemolysis or hyperbilirubinemia. 相似文献
7.
8.
Following the initial, sensory response to stimulus presentation, activity in many saccade-related burst neurons along the oculomotor neuraxis is observed as a gradually increasing low-frequency discharge hypothesized to encode both timing and metrics of the impending eye movement. When the activity reaches an activation threshold level, these cells discharge a high-frequency burst, inhibit the pontine omnipause neurons (OPNs) and trigger a high-velocity eye movement known as saccade. We tested whether early cessation of OPN activity, prior to when it ordinarily pauses, acts to effectively lower the threshold and prematurely trigger a movement of modified metrics and/or dynamics. Relying on the observation that OPN discharge ceases during not only saccades but also blinks, air-puffs were delivered to one eye to evoke blinks as monkeys performed standard oculomotor tasks. We observed a linear relationship between blink and saccade onsets when the blink occurred shortly after the cue to initiate the movement but before the average reaction time. Blinks that preceded and overlapped with the cue increased saccade latency. Blinks evoked during the overlap period of the delayed saccade task, when target location is known but a saccade cannot be initiated for correct performance, failed to trigger saccades prematurely. Furthermore, when saccade and blink execution coincided temporally, the peak velocity of the eye movement was attenuated, and its initial velocity was correlated with its latency. Despite the perturbations, saccade accuracy was maintained across all blink times and task types. Collectively, these results support the notion that temporal features of the low-frequency activity encode aspects of a premotor command and imply that inhibition of OPNs alone is not sufficient to trigger saccades. 相似文献
9.
Anna Scattone Gilda Caruso Andrea Marzullo Domenico Piscitelli Mattia Gentile Lucia Bonadonna Giuseppe Balducci Maria Cristina Digilio Alessandro Jenkner Francesca Diomedi Camassei Renata Boldrini Pietro Nazzaro Lucio Pollice Gabriella Serio 《Fetal and pediatric pathology》2003,22(4):323-341
Deletion 22q11.2 is a chromosomal abnormality detected in young patients with clinical manifestations of the DiGeorge/velocardiofacial syndrome. Conotruncal heart defects are also associated with del22q11.2. An association of these cardiac malformations with neoplasias has been observed. Our series includes two cases of malignancies, a hepatoblastoma and a renal-cell carcinoma, arising in children with complex cardiac malformations. The aim of the study was to determine if the deletion at 22q11.2 was present and could be responsible for both pathological processes. Del22q11.2 was identified in both cases. Comparative genomic hybridization revealed terminal gains on chromosomes 1q and Xq and terminal loss on 1p in the hepatoblastoma, and gains in 1p, 12q, 16p, 20q, 22q, and whole chromosome 19 and loss of Xq in the renal-cell carcinoma. Our results confirm a common genetic basis for cardiac malformations, and del22q11.2 presents a risk factor for the development of pediatric tumours. 相似文献
10.
Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. 总被引:6,自引:0,他引:6
Gianni Bonadonna Milvia Zambetti Angela Moliterni Luca Gianni Pinuccia Valagussa 《Journal of clinical oncology》2004,22(9):1614-1620
PURPOSE: To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of disease relapse. PATIENTS AND METHODS: Two randomized trials were activated in the early 1980s. The first study, in patients with one to three involved nodes, was intended to assess the effectiveness of intravenous (i.v.) CMF given every 3 weeks for 12 courses versus eight courses of the same CMF regimen followed by four courses of full-dose DOX (CMF-->DOX). The second study, in patients with more than three involved nodes, compared four courses of full-dose DOX sequentially followed by eight courses of i.v. CMF (DOX-->CMF) versus alternating two courses of the same CMF regimen with one course of DOX (CMF/DOX) for a total of 12 courses. RESULTS: After a median observation of 210 months, no statistically significant difference was documented in the first study (relapse-free survival hazard rate [HR], 1.06; total survival HR, 1.03). In contrast, the delivery of DOX first, followed by CMF significantly reduced the risk of disease relapse (HR, 0.68; 95% CI, 0.54 to 0.87; P =.0017) and death (HR, 0.74; 95% CI, 0.57 to 0.95; P =.018) compared with the alternating regimen. CONCLUSION: Anthracycline-containing regimens can further reduce the odds of relapse and death compared with CMF. However, the findings observed in our trials emphasize that the relative merits of anthracycline adjuvant programs also can depend on the modality of administration and must be assessed in properly designed trials in which the magnitude of the benefits can be weighed against potential risks. 相似文献